Missouri 2025 2025 Regular Session

Missouri Senate Bill SB219 Introduced / Bill

Filed 12/09/2024

                     
EXPLANATION-Matter enclosed in bold-faced brackets [thus] in this bill is not enacted 
and is intended to be omitted in the law. 
FIRST REGULAR SESSION 
SENATE BILL NO. 219 
103RD GENERAL ASSEMBLY  
INTRODUCED BY SENATOR BLACK. 
1393S.01I 	KRISTINA MARTIN, Secretary  
AN ACT 
To repeal section 336.010, RSMo, and to enact in lieu thereof one new section relating to the 
practice of optometry. 
 
Be it enacted by the General Assembly of the State of Missouri, as follows: 
     Section A.  Section 336.010, RSMo, is repealed and one new 1 
section enacted in lieu thereof, to be known as section 336.010, 2 
to read as follows:3 
     336.010.  1.  The "practice of optometry" is the  1 
examination, diagnosis, [treatment, and preventative care ]  2 
prevention, and treatment, surgical or nonsurgical, of the  3 
eye, adnexa, and vision.  The practice includes, but is not 4 
limited to: 5 
     (1)  The examination of the eye, adnex a, and vision to  6 
determine the accommodative and refractive states, visual 7 
perception, conditions, and diseases; 8 
     (2)  The diagnosis and treatment of conditions or 9 
diseases of the eye, adnexa, and vision; 10 
     (3)  The performance of diagnostic proc edures and  11 
ordering of laboratory and imaging tests for the diagnosis 12 
of vision and conditions and diseases of the eye and adnexa; 13 
     (4)  The prescription and administration of 14 
pharmaceutical agents [, excluding injectable agents, ] for  15 
the purpose of examination, diagnosis, and treatment of 16 
vision and conditions or diseases of the eye and adnexa; 17   SB 219 	2 
     (5)  The removal of superficial foreign bodies from the 18 
eye or adnexa; 19 
     (6)  Notwithstanding the provisions of any other law to 20 
the contrary, including section 334.010, the correction and 21 
relief of ocular abnormalities by surgical procedures not 22 
excluded under subsection 2 of this section; 23 
     (7)  The employment of objective or subjective 24 
mechanical means to determine the accommodative or 25 
refractive states of the human eye; 26 
     [(7)] (8)  The prescription or adaptation of lenses, 27 
prisms, devices, or ocular exercises to correct defects or 28 
abnormal conditions of the human eye or vision or to adjust 29 
the human eye to special conditions; 30 
     [(8)] (9)  The prescription and fitting of ophthalmic 31 
or contact lenses and devices; 32 
     [(9)] (10)  The prescription and administration of 33 
vision therapy; and 34 
     [(10)] (11)  The prescription and administration of low  35 
vision care. 36 
     2.  The board shall continue to review surgical 37 
procedures not listed in this subsection but which shall be 38 
excluded from the scope of the practice of optometry.  The  39 
following procedures are not within the scope of optometry 40 
and an optometrist [may] shall not perform [surgery,  41 
including the use of lasers for treatment of any disease or 42 
condition or for the correction of refractive error ] such  43 
procedures, except for the preoperative and postoperative 44 
care of these procedures: 45 
     (1)  Retina laser procedures, la ser-assisted in situ  46 
keratomileusis (LASIK), and photorefractive keratectomy 47 
(PRK); 48   SB 219 	3 
     (2)  Nonlaser surgery related to removal of the eye 49 
from a living human being; 50 
     (3)  Nonlaser surgery requiring full thickness incision 51 
or excision of the corn ea or sclera other than paracentesis 52 
in an emergency situation requiring immediate reduction of 53 
the pressure inside the eye; 54 
     (4)  Penetrating keratoplasty (corneal transplant) or 55 
lamellar keratoplasty; 56 
     (5)  Nonlaser surgery requiring incision of the iris  57 
and ciliary body, including iris diathermy or cryotherapy; 58 
     (6)  Nonlaser surgery requiring incision of the 59 
vitreous; 60 
     (7)  Nonlaser surgery requiring incision of the retina; 61 
     (8)  Nonlaser surgical extraction of the crystalline 62 
lens; 63 
     (9)  Nonlaser surgical intraocular implants; 64 
     (10)  Incisional or excisional nonlaser surgery of the 65 
extraocular muscles; 66 
     (11)  Nonlaser surgery of the eyelid for eyelid 67 
malignancies or for incisional cosmetic or mechanical repair 68 
of blepharochalasis, ptosis, and tarsorrhaphy; 69 
     (12)  Nonlaser surgery of the bony orbit, including 70 
orbital implants; 71 
     (13)  Incisional or excisional nonlaser surgery of the 72 
lacrimal system other than lacrimal probing or related 73 
procedures; 74 
     (14)  Nonlaser surgery requiring full thickness 75 
conjunctivoplasty with graft or flap; 76 
     (15)  Any nonlaser surgical procedure that does not 77 
provide for the correction and relief of ocular 78 
abnormalities; 79   SB 219 	4 
     (16)  Laser or nonlaser injection into the posterior  80 
chamber of the eye to treat any macular or retinal disease; 81 
and 82 
     (17)  The administration of general anesthesia . 83 
     3.  As used in this chapter, except as the context may 84 
otherwise require, the following terms mean: 85 
     (1)  "Eye", the human eye;  86 
     (2)  "Adnexa", all structures adjacent to the eye and 87 
the conjunctiva, lids, lashes, and lacrimal system; 88 
     (3)  "Board", the Missouri state board of optometry; 89 
     (4)  "Diagnostic pharmaceutical agents", topically 90 
applied pharmaceuticals used for the purpose of conducting 91 
an examination of the eye, adnexa, and vision; 92 
     (5)  "Low vision care", the examination, treatment, and 93 
management of patients with visual impairments not treatable 94 
by conventional eyewear or contact len ses and may include a 95 
vision rehabilitation program to enhance remaining vision 96 
skills;  97 
     (6)  "Pharmaceutical agents", any diagnostic and 98 
therapeutic drug or combination of drugs that assist the 99 
diagnosis, prevention, treatment, or mitigation of a bnormal  100 
conditions or symptoms of the human eye, adnexa, and vision; 101 
     (7)  "Therapeutic pharmaceutical agents", those 102 
pharmaceuticals[, excluding injectable agents, ] used for the  103 
treatment of conditions or diseases of the eye, adnexa, and 104 
vision;  105 
     (8)  "Vision therapy", a treatment regiment to improve 106 
a patient's diagnosed visual dysfunctions, prevent the 107 
development of visual problems, or enhance visual 108 
performance to meet the defined needs of the patient. 109 
